Hannah Deacon, Co-Founder of Maple Tree Consultancy and Campaigner ponders if the UK’s post-COVID-19 economy can benefit from a booming medical cannabis industry.
Rex Clements, CEO at Centrient Pharmaceuticals, discusses how the upcoming EU Pharma Strategy can prevent shortages and strengthen Europe’s manufacturing base, especially for antibiotics.
Dr. Christian Löfke, researcher and product developer at BioBloom in Austria explains CBG (cannabigerol), a “new” cannabinoid with vast potential in cannabis research.
Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.
Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.
Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.
Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.
Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.
